UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                  --------------------------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): November 5, 2003
                                                         ----------------

                               CYTOGEN CORPORATION
                 ----------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

         Delaware                     000-14879                 22-2322400
----------------------------   -----------------------      -------------------
(State or Other Jurisdiction   (Commission File Number)      (I.R.S. Employer
     of Incorporation)                                      Identification No.)

650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
---------------------------------------------------------   -------------------
       (Address of Principal Executive Offices)                  (Zip Code)

      Registrant's telephone number, including area code: (609) 750-8200
                                                          --------------




ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

     On November 5, 2003,  Cytogen  Corporation  announced its financial results
for the quarter  ended  September  30, 2003.  The full text of the press release
issued in connection  with the  announcement is attached as Exhibit 99.1 to this
Current Report on Form 8-K.

     The information in this Form 8-K and the exhibit  attached hereto shall not
be deemed "filed" for purposes of Section 18 of the  Securities  Exchange Act of
1934 (the  "Exchange  Act") or  otherwise  subject  to the  liabilities  of that
section,  nor shall it be deemed  incorporated  by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.





                                   SIGNATURES


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        CYTOGEN CORPORATION



                                        By: /s/ Michael D. Becker
                                           -------------------------------------
                                           Michael D. Becker
                                           President and Chief Executive Officer

Dated: November 5, 2003





                                  EXHIBIT INDEX


           Exhibit No.     Description
           -----------     -----------

                 99.1      Press release dated November 5, 2003.